-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Orelabrutinib is a novel small molecule selective irreversible Bruton tyrosine kinase inhibitor
This is a prospective, multicenter clinical trial that enrolled patients with R/R WM who
Between August 2019 and December 2020, a total of 66 patients with
For patients with MYD88L265P/CXCR4NEG, MYD88L265P/CXCR4S338X, or MYD88NEG/CXCR4NEG mutations, MRR was 84.
Most of the adverse reactions were grade 1-2 (91.
In summary, Orelabrutinib has demonstrated good efficacy and controlled safety
Original Source:
Xin-xin Cao, et al.